Adjuvant Therapy Recommendation for Stage IB3 (pT1b3, pN0) Cervical Cancer
For this patient with stage IB3 cervical cancer who is node-negative after adequate lymph node sampling (14 nodes examined), adjuvant pelvic external beam radiotherapy (EBRT) with concurrent platinum-based chemotherapy is recommended if intermediate-risk factors (Sedlis criteria) are present; otherwise, observation alone is appropriate.
Risk Stratification Framework
Your treatment decision hinges on identifying intermediate-risk features (Sedlis criteria) in this node-negative patient 1:
Sedlis Criteria (Intermediate-Risk Factors):
- Deep stromal invasion (>1/3 depth)
- Lymphovascular space invasion (LVSI)
- Large tumor size (≥4 cm)
If 2 or more of these factors are present, adjuvant therapy is indicated 1, 2.
Treatment Algorithm
Scenario 1: No Sedlis Criteria or Only 1 Factor Present
- Observation only is appropriate 1
- No adjuvant therapy needed despite IB3 stage designation
- Close surveillance with regular follow-up
Scenario 2: ≥2 Sedlis Criteria Present (Intermediate-Risk)
Adjuvant pelvic EBRT is recommended (Category 1 evidence) 1
Chemotherapy addition:
- Concurrent platinum-based chemotherapy is Category 2B recommendation 1
- Preferred regimen: Cisplatin (radiosensitizing dose)
- Alternative: Carboplatin (if cisplatin intolerant) 1
Rationale: The landmark GOG 92 trial demonstrated that adjuvant pelvic RT in intermediate-risk, node-negative stage IB patients improved 2-year recurrence-free rates from 79% to 88%, with sustained progression-free survival benefit at 12-year follow-up 2. The absolute benefit was particularly pronounced in adenocarcinoma/adenosquamous histologies, where recurrence dropped from 44% to 8.8% with radiotherapy 2.
Critical Pathology Details to Review
You must verify these specific pathologic features to properly risk-stratify:
- Depth of stromal invasion (measure in mm and calculate percentage)
- Presence/absence of LVSI
- Actual tumor diameter (should be ≥4 cm for IB3, but confirm)
- Histologic subtype (squamous vs. adenocarcinoma/adenosquamous)
- Surgical margin status (must be negative for intermediate-risk category)
- Parametrial involvement (must be negative for intermediate-risk category)
Important Caveats
Adequate Lymph Node Assessment
Your patient had 14 pelvic nodes examined, which represents adequate sampling. This supports the validity of the pN0 designation and makes observation more defensible if intermediate-risk criteria are absent 3.
Histology Matters
If the tumor is adenocarcinoma or adenosquamous, there is stronger evidence for adjuvant RT benefit even with intermediate-risk features, showing a 5-fold reduction in recurrence risk 2.
High-Risk Features Exclusion
This patient does NOT have high-risk features (positive nodes, positive margins, or parametrial involvement), so the more aggressive Category 1 recommendation for concurrent chemoradiation does not automatically apply 1.
Surveillance Strategy
Regardless of adjuvant therapy decision:
- Clinical examination every 3-4 months for first 2 years
- Then every 6 months until year 5
- Annual examinations thereafter
- Imaging only for symptomatic concerns (not routine surveillance)
Common Pitfall to Avoid
Do not automatically treat all IB3 patients with adjuvant therapy. The stage designation alone does not mandate treatment—you must assess the specific Sedlis criteria. Recent evidence suggests that in carefully selected patients with adequate surgery and negative nodes, observation can provide similar outcomes to adjuvant therapy, avoiding overtreatment 3. The key is identifying which patients truly have intermediate-risk disease requiring intervention versus those who can be safely observed.